LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX
· Real-Time Price · USD
1.53
0.01 (0.66%)
At close: Aug 18, 2025, 3:04 PM
LAVA Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 4.99M | n/a | n/a | 6.99M | 353K | 53K | 5.14M | 1.22M | 2.64M | 15.26M | 468K | 1.02M | 1.07M | 2.1M | 1.08M | 1M |
Cost of Revenue | n/a | 228K | n/a | 228K | n/a | 154K | 10K | 2.39M | 930K | n/a | n/a | n/a | n/a | 6.63M | 6.7M | 4.89M | 18.71M |
Gross Profit | n/a | 4.99M | n/a | -228K | 6.99M | 199K | 43K | 2.75M | 294K | 2.64M | 15.26M | 468K | 1.02M | -5.57M | -4.61M | -3.81M | -17.71M |
Operating Income | n/a | -7.1M | -11.29M | -9.36M | -1.95M | -5.44M | -10.73M | -13.54M | -13.54M | -11.48M | -1.57M | -11.08M | -10.71M | -9.34M | -8.37M | -6.58M | -19.44M |
Interest Income | 713K | 1.33M | 805K | 811K | 810K | 846K | 809K | 698K | 617K | 471K | 39K | 90K | n/a | 151K | 158K | n/a | n/a |
Pretax Income | -3.7M | -3.59M | -12.2M | -8.21M | -484K | -6.44M | -8.79M | -12.6M | -13.87M | -14.85M | 983K | -8.03M | -9.76M | -8.16M | -6.89M | -8.01M | -19.72M |
Net Income | -3.48M | -3.97M | -12.3M | -8.3M | -553K | -6.5M | -8.84M | -12.7M | -13.94M | -14.91M | 936K | -8.11M | -9.82M | -8.22M | -6.93M | -8.04M | -19.74M |
Selling & General & Admin | 3.43M | 4.48M | 2.79M | 3.02M | 2.94M | 2.28M | 2.86M | 3.7M | 3.89M | 3.58M | 3.13M | 3.17M | 4.24M | 3.77M | 3.76M | 2.76M | 1.73M |
Research & Development | 4.16M | 7.61M | 8.5M | 6.34M | 6.01M | 3.36M | 7.91M | 12.6M | 9.94M | 10.54M | 13.7M | 8.37M | 7.5M | 6.63M | 6.7M | 4.89M | 18.71M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 7.59M | 11.91M | 11.29M | 9.36M | 8.29M | 7.48M | 9.64M | 16.05M | 14.78M | 17.96M | 14.32M | 8.41M | 10.62M | 2.44M | 2.12M | 4M | 1.88M |
Interest Expense | 129K | 515K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 90K | 163K | 132.04K | 186.74K | 187K | 129K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 7.59M | 12.09M | 11.29M | 9.36M | 8.29M | 7.64M | 9.65M | 18.44M | 15.71M | 17.96M | 14.32M | 8.41M | 10.62M | 9.08M | 8.83M | 8.9M | 20.59M |
Income Tax Expense | -225K | 380K | 96K | 85K | 69K | 61K | 50K | 97K | 71K | 67K | 47K | 76K | 59K | 57K | 44K | 32K | 24K |
Shares Outstanding (Basic) | 26.89M | 26.87M | 26.85M | 26.82M | 26.79M | 26.77M | 26.29M | 26.29M | 26.29M | 26.29M | 25.85M | 25.78M | 25.78M | 25.78M | 25.68M | 25.52M | 25.52M |
Shares Outstanding (Diluted) | 26.89M | 26.87M | 26.85M | 26.82M | 26.79M | 26.77M | 26.29M | 26.29M | 26.29M | 26.29M | 26.45M | 25.78M | 25.78M | 25.78M | 25.78M | 25.52M | 25.52M |
EPS (Basic) | -0.13 | -0.15 | -0.46 | -0.31 | -0.02 | -0.24 | -0.34 | -0.48 | -0.53 | -0.57 | 0.04 | -0.31 | -0.38 | -0.32 | -0.27 | -0.31 | -0.77 |
EPS (Diluted) | -0.13 | -0.15 | -0.46 | -0.31 | -0.02 | -0.24 | -0.34 | -0.48 | -0.53 | -0.57 | 0.04 | -0.31 | -0.38 | -0.32 | -0.27 | -0.31 | -0.77 |
EBITDA | n/a | -3.37M | -11.07M | -9.24M | -1.81M | -5.26M | -10.57M | -13.39M | -13.23M | -11.29M | -1.47M | -10.97M | -10.61M | -9.24M | -8.28M | -6.72M | -19.37M |
EBIT | n/a | -3.37M | -11.29M | -9.36M | -1.95M | -3.65M | -10.73M | -13.54M | -13.54M | -8.3M | -1.57M | -11.08M | -10.71M | -10.57M | -8.37M | -7.82M | -19.59M |
Depreciation & Amortization | n/a | -584K | 212K | 228K | 144K | 183K | 152K | 152K | 129K | 189K | 105K | 109K | 101K | 96K | 87K | 77K | 71K |